Advanced/Metastatic Solid Tumors Clinical Trials

30 clinical trials for Advanced/Metastatic Solid Tumors across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors — RECRUITING · PHASE1
• A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors — RECRUITING · PHASE1
• A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors — RECRUITING · PHASE1
• A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors — RECRUITING · PHASE1
• A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors — RECRUITING · PHASE1
• A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors — RECRUITING · PHASE1
• A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors — RECRUITING · PHASE1
• Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors — RECRUITING · PHASE1
• ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors — RECRUITING · PHASE1
• Study of MHB088C for Patients With Advanced Solid Malignant Tumors — RECRUITING · PHASE1
• First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma — RECRUITING · PHASE1
• Immunotherapy Master Trial for Advanced Cancers — NOT_YET_RECRUITING · PHASE2
• A study to assess safety and efficacy of SOT201 in patients with advance/metastatic cancer — TERMINATED · PHASE1
• Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor — NOT_YET_RECRUITING · PHASE1
• A Study of FDA018-ADC in Patients With Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients — COMPLETED · PHASE1
• Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) — COMPLETED · PHASE1
• A phase I/II trial of IOMX-0675 a fully human monoclonal antibody selectively inhibiting LILRB1/2 alone or in combination with pembrolizumab in patients with previously treated advanced/metastatic solid tumors (LIMNOS) — NOT_YET_RECRUITING · PHASE1
• Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001) — TERMINATED · PHASE1
• Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors — TERMINATED · PHASE1
• ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors — COMPLETED · PHASE1
• A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors — OTHER · PHASE1
• ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors — COMPLETED · PHASE1
• A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors — OTHER · PHASE1
• Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors — COMPLETED · PHASE1
• A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors — TERMINATED · PHASE1
• Study of NMS-1116354 in Advanced/Metastatic Solid Tumors — TERMINATED · PHASE1
• Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors — TERMINATED · PHASE1

Refine this search